Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results
Author:
Cervantes,
C..
v.
97
no.
Supp 1,
pp.
239
Date:
2012
ISSN:
0390-6078,
DOI: